247 related articles for article (PubMed ID: 12131530)
1. Early decline in the catecholamine release-inhibitory peptide catestatin in humans at genetic risk of hypertension.
O'Connor DT; Kailasam MT; Kennedy BP; Ziegler MG; Yanaihara N; Parmer RJ
J Hypertens; 2002 Jul; 20(7):1335-45. PubMed ID: 12131530
[TBL] [Abstract][Full Text] [Related]
2. Expression of altered alpha2-adrenergic phenotypic traits in normotensive humans at genetic risk of hereditary (essential) hypertension.
Dao TT; Kailasam MT; Parmer RJ; Le HV; Le Verge R; Kennedy BP; Ziegler G; Insel PA; Wright FA; O'Connor DT
J Hypertens; 1998 Jun; 16(6):779-92. PubMed ID: 9663918
[TBL] [Abstract][Full Text] [Related]
3. The catecholamine release-inhibitory "catestatin" region of chromogranin a: early decline in humans at genetic risk of hypertension.
O'Connor DT; Kailasam MT; Kennedy BP; Ziegler MG; Yanaihara N; Parmer RJ
Ann N Y Acad Sci; 2002 Oct; 971():533-5. PubMed ID: 12438176
[No Abstract] [Full Text] [Related]
4. The chromogranin A fragment catestatin: specificity, potency and mechanism to inhibit exocytotic secretion of multiple catecholamine storage vesicle co-transmitters.
Mahapatra NR; Mahata M; Mahata SK; O'Connor DT
J Hypertens; 2006 May; 24(5):895-904. PubMed ID: 16612252
[TBL] [Abstract][Full Text] [Related]
5. Catecholamine release-inhibitory peptide catestatin (chromogranin A(352-372)): naturally occurring amino acid variant Gly364Ser causes profound changes in human autonomic activity and alters risk for hypertension.
Rao F; Wen G; Gayen JR; Das M; Vaingankar SM; Rana BK; Mahata M; Kennedy BP; Salem RM; Stridsberg M; Abel K; Smith DW; Eskin E; Schork NJ; Hamilton BA; Ziegler MG; Mahata SK; O'Connor DT
Circulation; 2007 May; 115(17):2271-81. PubMed ID: 17438154
[TBL] [Abstract][Full Text] [Related]
6. Catecholamine secretory vesicle stimulus-transcription coupling in vivo. Demonstration by a novel transgenic promoter/photoprotein reporter and inhibition of secretion and transcription by the chromogranin A fragment catestatin.
Mahata SK; Mahapatra NR; Mahata M; Wang TC; Kennedy BP; Ziegler MG; O'Connor DT
J Biol Chem; 2003 Aug; 278(34):32058-67. PubMed ID: 12799369
[TBL] [Abstract][Full Text] [Related]
7. Catestatin is a novel endogenous peptide that regulates cardiac function and blood pressure.
Mahapatra NR
Cardiovasc Res; 2008 Dec; 80(3):330-8. PubMed ID: 18541522
[TBL] [Abstract][Full Text] [Related]
8. Hypertension from targeted ablation of chromogranin A can be rescued by the human ortholog.
Mahapatra NR; O'Connor DT; Vaingankar SM; Hikim AP; Mahata M; Ray S; Staite E; Wu H; Gu Y; Dalton N; Kennedy BP; Ziegler MG; Ross J; Mahata SK
J Clin Invest; 2005 Jul; 115(7):1942-52. PubMed ID: 16007257
[TBL] [Abstract][Full Text] [Related]
9. The catecholamine release-inhibitory "catestatin" fragment of chromogranin a: naturally occurring human variants with different potencies for multiple chromaffin cell nicotinic cholinergic responses.
Mahata SK; Mahata M; Wen G; Wong WB; Mahapatra NR; Hamilton BA; O'Connor DT
Mol Pharmacol; 2004 Nov; 66(5):1180-91. PubMed ID: 15326220
[TBL] [Abstract][Full Text] [Related]
10. Desensitization of catecholamine release. The novel catecholamine release-inhibitory peptide catestatin (chromogranin a344-364) acts at the receptor to prevent nicotinic cholinergic tolerance.
Mahata SK; Mahata M; Parmer RJ; O'Connor DT
J Biol Chem; 1999 Jan; 274(5):2920-8. PubMed ID: 9915830
[TBL] [Abstract][Full Text] [Related]
11. Formation of the catecholamine release-inhibitory peptide catestatin from chromogranin A. Determination of proteolytic cleavage sites in hormone storage granules.
Taylor CV; Taupenot L; Mahata SK; Mahata M; Wu H; Yasothornsrikul S; Toneff T; Caporale C; Jiang Q; Parmer RJ; Hook VY; O'Connor DT
J Biol Chem; 2000 Jul; 275(30):22905-15. PubMed ID: 10781584
[TBL] [Abstract][Full Text] [Related]
12. Analysis and validation of traits associated with a single nucleotide polymorphism Gly364Ser in catestatin using humanized chromogranin A mouse models.
Mir SA; Zhang K; Milic M; Gu Y; Rieg T; Ziegler M; Vaingankar SM
J Hypertens; 2016 Jan; 34(1):68-78. PubMed ID: 26556564
[TBL] [Abstract][Full Text] [Related]
13. Chromogranin A in human hypertension. Influence of heredity.
Takiyyuddin MA; Parmer RJ; Kailasam MT; Cervenka JH; Kennedy B; Ziegler MG; Lin MC; Li J; Grim CE; Wright FA
Hypertension; 1995 Jul; 26(1):213-20. PubMed ID: 7607727
[TBL] [Abstract][Full Text] [Related]
14. Mechanism of action of chromogranin A on catecholamine release: molecular modeling of the catestatin region reveals a beta-strand/loop/beta-strand structure secured by hydrophobic interactions and predictive of activity.
Tsigelny I; Mahata SK; Taupenot L; Preece NE; Mahata M; Khan I; Parmer RJ; O'Connor DT
Regul Pept; 1998 Oct; 77(1-3):43-53. PubMed ID: 9809795
[TBL] [Abstract][Full Text] [Related]
15. Identification of novel loci affecting circulating chromogranins and related peptides.
Benyamin B; Maihofer AX; Schork AJ; Hamilton BA; Rao F; Schmid-Schönbein GW; Zhang K; Mahata M; Stridsberg M; Schork NJ; Biswas N; Hook VY; Wei Z; Montgomery GW; Martin NG; Nievergelt CM; Whitfield JB; O'Connor DT
Hum Mol Genet; 2017 Jan; 26(1):233-242. PubMed ID: 28011710
[TBL] [Abstract][Full Text] [Related]
16. Primary structure and function of the catecholamine release inhibitory peptide catestatin (chromogranin A(344-364)): identification of amino acid residues crucial for activity.
Mahata SK; Mahata M; Wakade AR; O'Connor DT
Mol Endocrinol; 2000 Oct; 14(10):1525-35. PubMed ID: 11043569
[TBL] [Abstract][Full Text] [Related]
17. Heritability and genome-wide linkage in US and australian twins identify novel genomic regions controlling chromogranin a: implications for secretion and blood pressure.
O'Connor DT; Zhu G; Rao F; Taupenot L; Fung MM; Das M; Mahata SK; Mahata M; Wang L; Zhang K; Greenwood TA; Shih PA; Cockburn MG; Ziegler MG; Stridsberg M; Martin NG; Whitfield JB
Circulation; 2008 Jul; 118(3):247-57. PubMed ID: 18591442
[TBL] [Abstract][Full Text] [Related]
18. Interaction of the catecholamine release-inhibitory peptide catestatin (human chromogranin A(352-372)) with the chromaffin cell surface and Torpedo electroplax: implications for nicotinic cholinergic antagonism.
Taupenot L; Mahata SK; Mahata M; Parmer RJ; O'Connor DT
Regul Pept; 2000 Nov; 95(1-3):9-17. PubMed ID: 11062327
[TBL] [Abstract][Full Text] [Related]
19. Circulating amylin in human essential hypertension: heritability and early increase in individuals at genetic risk.
Kailasam MT; Parmer RJ; Tyrell EA; Henry RR; O'Connor DT
J Hypertens; 2000 Nov; 18(11):1611-20. PubMed ID: 11081774
[TBL] [Abstract][Full Text] [Related]
20. The relationship of plasma catestatin concentrations with metabolic and vascular parameters in untreated hypertensive patients: Influence on high-density lipoprotein cholesterol.
Durakoğlugil ME; Ayaz T; Kocaman SA; Kırbaş A; Durakoğlugil T; Erdoğan T; Çetin M; Şahin OZ; Çiçek Y
Anatol J Cardiol; 2015 Jul; 15(7):577-85. PubMed ID: 25538000
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
